Presidio, Boehringer to evaluate all-oral HCV regimen

Presidio Pharmaceuticals Inc. (San Francisco, Calif.) and Boehringer Ingelheim GmbH (Ingelheim, Germany) non-exclusively partnered to evaluate an all-oral regimen of the companies' HCV compounds in a Phase IIa trial. The trial, which is slated to start in 2Q13, will evaluate Presidio's PPI-668 in combination with Boehringer's faldaprevir ( BI 201335) and BI 207127 with or without ribavirin. Data are expected in 4Q13. The companies retain all rights to their respective compounds. ...